Merck and Google Cloud Bring Agentic AI Into Biopharma Workflows

Merck and Google Cloud announced a multi-year partnership on April 22, 2026, at Google Cloud Next. The investment is valued at up to $1 billion and will use Google Cloud technology, including Gemini Enterprise, to build an agentic AI platform across Merck’s business. Merck is known as MSD outside the United States and Canada.

The scope of the partnership is broad. Merck says the platform will support research and development, manufacturing, commercial work, and corporate functions. Google Cloud engineers will work directly with Merck teams to deploy AI across the company’s digital backbone. The goal is to improve productivity for Merck’s 75,000 employees worldwide and support the company during a major product launch period.

This is important because biopharma is a highly regulated industry where AI adoption needs practical controls. A generic chatbot can answer questions, but an enterprise biopharma AI system has to work with scientific data, regulatory documents, manufacturing requirements, approval workflows, commercial operations, and patient-facing processes. In this type of environment, usefulness depends on traceability, review steps, access controls, and clear ownership.

Merck’s announcement lists several operational areas where the partnership is expected to apply AI. These include end-to-end R&D workflows, manufacturing optimization through predictive analytics and intelligent automation, commercial and patient engagement through data-driven personalization, and AI-powered automation in corporate functions.

The R&D angle is the most obvious. Drug development involves scientific literature, trial data, protocols, reports, regulatory requirements, and internal decision records. Agentic AI can help teams search, summarize, compare, and prepare research material faster. Reuters reported that Merck has already used AI for clinical report automation and regulatory dossier preparation, reducing time and cost.

Regulatory work is a strong use case because it is document-heavy and process-heavy. Teams need to prepare submissions, check consistency, update supporting documents, compare information across files, and maintain evidence trails. AI agents can assist with drafting, checking, retrieval, summarisation, and workflow routing. Human review remains necessary because mistakes in regulated documentation can create compliance and patient-safety risks.

Manufacturing is another practical area. In biopharma, manufacturing systems depend on quality control, equipment performance, batch consistency, supply planning, maintenance, and deviation management. Merck says the partnership will use predictive analytics and intelligent automation in manufacturing. That suggests AI will be used for operational decisions, not only office productivity tasks.

Commercial and patient engagement use cases are also part of the announcement. In practical terms, this can include better segmentation, content support, customer engagement planning, field-team assistance, market access support, and personalization based on approved data. In regulated sectors, these systems need guardrails around claims, approved language, privacy, and medical accuracy.

The phrase “agentic AI” matters here. A normal AI assistant usually waits for a user prompt and gives a response. An agentic system can plan steps, use tools, search approved sources, trigger workflows, and assist across a process. In a company like Merck, that could mean helping a team move from research material to a draft report, from manufacturing data to an exception summary, or from commercial data to an approved engagement plan.

Gemini Enterprise is central to the partnership. Google positions Gemini Enterprise as an AI assistant and agentic platform for company workflows. DCAT’s industry report describes the Merck deal as a deployment of Gemini Enterprise across R&D, manufacturing, commercial, and corporate functions, with Google Cloud engineers working alongside Merck teams.

The business signal is clear. Large companies are moving AI from isolated pilots into operational platforms. In biopharma, that means AI needs to connect with existing systems, follow rules, respect data boundaries, support audits, and fit into real employee workflows. The value comes from reducing manual work in high-volume processes while keeping expert review in place.

For healthcare and life-science companies, the Merck and Google Cloud deal is a useful marker. AI adoption in regulated industries is likely to grow first in workflows where the work is repetitive, document-heavy, data-heavy, and reviewable. Good examples include clinical documentation, regulatory preparation, quality operations, manufacturing analytics, literature review, internal knowledge search, medical affairs support, and commercial planning.

The partnership also shows that enterprise AI is becoming a long-term infrastructure decision. Merck is not only buying access to a model. It is investing in a platform, cloud engineering support, enterprise workflows, and operating changes across the business. That is a different level of commitment from testing a chatbot inside one department.

For business leaders, the lesson is direct. Agentic AI is most useful when it is tied to measurable operations. The right questions are not “Can we use AI?” or “Which model is best?” The useful questions are: which workflow takes too long, where is the data, who approves the output, what risks need controls, and how will improvement be measured?

Merck and Google Cloud’s partnership shows where regulated AI adoption is heading. The most credible use cases are not flashy demos. They are structured systems that help expert teams work faster across research, regulatory, manufacturing, commercial, and corporate processes.